Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4Observational 1

Sponsor

Conditions

Breast Neoplasms 10163Neoplasms 7801Carcinoma, Non-Small-Cell Lung 5744Prostatic Neoplasms 5016Colorectal Neoplasms 4588Lung Neoplasms 3716Leukemia, Myeloid, Acute 3097Neoplasm Metastasis 3074Multiple Myeloma 3073Pancreatic Neoplasms 2837Melanoma 2646Lymphoma 2569Ovarian Neoplasms 2565Carcinoma, Hepatocellular 2473Stomach Neoplasms 2325Recurrence 2221Head and Neck Neoplasms 2095Precursor Cell Lymphoblastic Leukemia-Lymphoma 2084Lymphoma, Non-Hodgkin 2055Leukemia 2011Brain Neoplasms 1899Glioblastoma 1791Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1714Uterine Cervical Neoplasms 1684Lymphoma, Follicular 1651Squamous Cell Carcinoma of Head and Neck 1649Lymphoma, Large B-Cell, Diffuse 1596Carcinoma, Renal Cell 1574

Interventions

enzalutamide 2tislelizumab 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × mCRPC × Clear all
NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting
1,054 enrolled 21 charts 1 FDA

mCRPC

NCT07389187 2026-02-05

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled

mCRPC

NCT07104643 2025-08-05

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)

TYK Medicines, Inc

Phase 1/2 Not yet recruiting
48 enrolled

mCRPC

NCT07096128 2025-07-31

A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

Chinese PLA General Hospital

Phase 1 Recruiting
36 enrolled

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡